MindMed appoints Stanford University neuroscientist as chair of scientific advisory board

Mind Medicine Inc (MindMed) (NEO:MMED), (OTCQB:MMEDF), (FRA:MMQ) said it has appointed Robert C. Malenka, an accomplished neuroscientist and psychiatry professor from Stanford University, to chair its scientific advisory board. 

Malenka is an elected member of the National Academy of Sciences and the National Academy of Medicine, as well as an elected fellow of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the American College of Neuropsychopharmacology. 

READ: MindMed added to two leading FTSE Russell indexes

He has also served on the National Advisory Council on Drug Abuse and as a Counselor for the Society for Neuroscience and the American College of Neuropsychopharmacology.

“I am very excited to join the MindMed team and to help bring creative, sophisticated and rigorous scientific approaches to advancing MindMed’s mission of developing new, more efficacious treatments to potentially improve the mental health of the large segments of the population in need. There are incredible opportunities to leverage the use of previously demonized drugs as therapies and combine them with other treatment modalities to potentially achieve more rapid, more effective and longer-lasting reductions in symptoms that often destroy lives and families. New approaches for improving mental health are desperately needed, and I look forward to working with MindMed on such approaches,” Malenka said in a statement.

“Dr. Malenka has tremendous knowledge and wisdom across several critical fields in which MindMed operates. We are honored to have him join MindMed as Chair of the Scientific Advisory Board. The entire MindMed team is elated to learn and receive guidance from an industry veteran who has guided several pharmaceutical and biotechnology companies throughout their growth and development. As the MindMed team progresses toward achieving MindMed’s goal of providing innovative new potential treatments to the mental health and addiction patient populations, we look forward to Dr. Malenka’s input and guidance,” added MindMed chief executive J.R. Rahn.

Contact the author at [email protected]

Follow him on Twitter @Cal_Proac

Story by ProactiveInvestors